Mortality and Institutionalisation Following de Novo Use of Rotigotine Patches in Hospitalised Patients with Parkinson’s Disease
Objective: Guidelines recommend use of rotigotine patches as an option if Parkinson’s patients are unable to take their usual oral medication, but this strategy has…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Course of Impulse Control Disorder in People Living with Parkinson’s Disease: A Longitudinal Study on Dopamine Agonist Treatment
Objective: To compare the incidence and severity of ICDs among PwP treated with different DA, specifically examining their respective impacts on ICD onset and remission.…Dopa-Responsive Parkinsonism Secondary to Tauopathy: Clinical, Pathological, and Genetic Study
Objective: To report on the clinical, pathological, and genetic findings of four cases of levodopa-responsive parkinsonism with long survival and tauopathy. Background: The most common…A Novel Dopaminergic Modulator (NDM-101) as an Adjunct to Levodopa: Enhancing Motor Control Without Worsening Dyskinesia in Parkinson’s Disease
Objective: To evaluate the efficacy and safety of NDM-101 as an adjunct to levodopa in reducing OFF-time, improving motor function, and maintaining quality of life…Changes in Motor States Throughout the Waking Day With Tavapadon in People With Parkinson’s Disease
Objective: To evaluate motor states throughout the waking day when adding tavapadon to oral carbidopa/levodopa in adults with Parkinson’s disease experiencing motor fluctuations. Background: Long-term…Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study
Objective: Use heatmap analysis to quantify and examine diurnal patterns of OFF and GOOD ON time periods throughout the day, and changes in the number…Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays
Objective: Characterize the functional activity of apomorphine relative to dopamine using a modern panel of G protein-coupled receptor biosensor assays. Background: The structural similarity of…Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…
- 1
- 2
- 3
- …
- 15
- Next Page »